CDMO:NSD-Avid Bioservices Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 31.50

Change

+0.95 (+3.11)%

Market Cap

USD 1.87B

Volume

0.68M

Avg Analyst Target

USD 28.00 (-11.11%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Avid Bioservices Inc (CDMO) Stock Analysis:
Based on the Avid Bioservices Inc stock forecasts from 3 analysts, the average analyst target price for Avid Bioservices Inc is USD 28.00 over the next 12 months. Avid Bioservices Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Avid Bioservices Inc is Slightly Bullish , which is based on 8 positive signals and 6 negative signals. At the last closing, Avid Bioservices Inc’s stock price was USD 31.50. Avid Bioservices Inc’s stock price has changed by -0.07 % over the past week, -1.18 % over the past month and +184.81 % over the last year.

About

Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell cult ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-12-02 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-9.12 (-2.94%)

USD149.41B 18.61 18.13
BNTX BioNTech SE

-0.99 (-0.30%)

USD85.30B 11.13 8.07
REGN Regeneron Pharmaceuticals Inc

+3.41 (+0.54%)

USD70.38B 10.09 8.03
VRTX Vertex Pharmaceuticals Incorpo..

-0.55 (-0.27%)

USD48.34B 24.59 14.41
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

-6.11 (-1.74%)

USD33.10B N/A N/A
SGEN Seagen Inc

+0.42 (+0.27%)

USD29.26B 55.02 44.86
GMAB Genmab A/S

-0.54 (-1.42%)

USD25.19B 58.75 6.30
ALNY Alnylam Pharmaceuticals Inc

+2.92 (+1.62%)

USD21.98B N/A N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing CDMO

Symbol Name Weight Mer Price(Change) Market Cap

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 172.96% 95% A 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 172.96% 95% A 97% A+
Trailing 12 Months  
Capital Gain 184.81% 95% A 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 184.81% 95% A 96% A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 70.26% 82% B- 89% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 70.26% 82% B- 89% B+
Risk Return Profile  
Volatility (Standard Deviation) 99.88% 27% F 16% F
Risk Adjusted Return 70.34% 92% A- 83% B
Market Capitalization 1.87B 85% B 75% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 285.51 5% F 5% F
Price/Book Ratio 41.82 2% F 2% F
Price / Cash Flow Ratio 59.86 2% F 7% F
EV/EBITDA 102.36 6% F 9% F
Management Effectiveness  
Return on Equity 28.05% 98% A+ 92% A-
Return on Invested Capital 11.08% 88% B+ 80% B-
Return on Assets 4.80% 94% A 78% C+
Debt to Equity Ratio 124.72% 10% F 16% F
Technical Ratios  
Short Ratio 3.82 53% F 37% F
Short Percent 11.72% 14% F 14% F
Beta 2.29 8% F 7% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.